Business Context and Reporting Period
This Form 6-K filing by Medirom Healthcare Technologies Inc. covers the month of February 2026, with a filing date of February 3, 2026. The report details significant capital restructuring transactions involving the issuance of new convertible bonds, the refinancing of maturing debt, and the establishment of a secured loan agreement with Kufu Company Holdings Inc.
Key Financial Metrics and Capital Structure
- Convertible Bond Issuance: Issued Fourth Unsecured Convertible-Type Corporate Bonds with Share Options totaling JPY 275,000,000 on December 31, 2025.
- Debt Refinancing: Refinanced JPY 275,000,000 of principal from maturing "1st Bonds" into the new convertible bonds and JPY 200,000,000 into a new deemed loan.
- Cash Repayment: Repaid JPY 25,000,000 of the maturing 1st Bonds in cash on December 31, 2025.
- Deemed Loan Terms: Established a JPY 200,000,000 loan bearing 10.0% annual interest, due March 31, 2026.
- Convertible Bond Terms: Interest rate of 5.0% per annum; maturity date of June 30, 2026 (extendable to December 25, 2026); conversion price of JPY 330 per share.
- Collateral: Pledged all shares of subsidiary MEDIROM MOTHER Labs Inc. (MML) to secure the JPY 200,000,000 loan.
Material Changes Versus Prior Period
The filing reports a material shift in the company's debt structure following the maturity of JPY 500,000,000 in "1st Bonds" issued in December 2022. Instead of full cash repayment, the company executed a partial refinancing strategy:
- Converted JPY 275,000,000 of principal into equity-linked convertible debt.
- Converted JPY 200,000,000 of principal into a short-term, high-interest secured loan.
- Retained only JPY 25,000,000 for immediate cash settlement.
Guidance, Risks, and Contingencies
The filing contains no specific financial guidance or revenue outlook. However, it highlights significant risks and contingencies associated with the new debt instruments:
- Acceleration Clauses: Both the convertible bonds and the deemed loan allow the bondholder to demand immediate repayment upon events such as failure to pay interest, bankruptcy proceedings, suspension of business operations, or significant damage to creditworthiness.
- Security Interest: The bondholder holds a first-priority security interest in all shares of the MML subsidiary. Upon acceleration of the loan, the bondholder may dispose of these shares without prior notice.
- Delinquency Penalties: Overdue interest or principal incurs a delinquency interest rate of 14.6% per annum.
- Forward-Looking Statements: The company cautions that actual results may differ from expectations and that the transactions may not be consummated or may adversely impact financial condition.
Investor Verification Checklist
- Verify the current market price of Medirom common stock relative to the JPY 330 conversion price to assess the likelihood of conversion.
- Confirm the company's ability to repay the JPY 200,000,000 loan by the March 31, 2026 deadline.
- Review the financial health and strategic importance of the pledged subsidiary, MEDIROM MOTHER Labs Inc.
- Check for any subsequent filings regarding the extension of the convertible bond maturity date to December 2026.
- Monitor for any default events that could trigger immediate acceleration of the JPY 475,000,000 in refinanced debt.